Tomasz Stys, MD
Interventional Cardiology · Sioux Falls, SDNPI 1891790978
Payments from drug & device makers
Across 549 payments — averaging $1235.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$455K
- Cardiovascular Systems Inc.$209K
- Janssen Research & Development, LLC$8K
- Medtronic$3K
- Johnson & Johnson$510
- Abiomed$482
- plus $2K from 21 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Travel & lodging$2,90231%
- Food & beverage$6,16767%
- Education$1632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 242 | $454,787 |
| Cardiovascular Systems Inc. | 39 | $209,482 |
| Janssen Research & Development, LLC | 6 | $7,664 |
| Medtronic(2 entities) | 62 | $3,239 |
| Johnson & Johnson | 63 | $510 |
| Abiomed | 13 | $482 |
| E.r. Squibb & Sons, L.L.C. | 25 | $308 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $298 |
| AstraZeneca | 16 | $222 |
| Boston Scientific | 7 | $176 |
| Edwards Lifesciences | 14 | $144 |
| Novo Nordisk | 4 | $129 |
| Atricure, Inc. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Chiesi USA, Inc. | 6 | $76 |
| Pfizer | 3 | $58 |
| Amarin Pharma, Inc. | 4 | $51 |
| Amgen | 3 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Reflow Medical Inc | 1 | $35 |
| BD | 1 | $33 |
| Shockwave Medical, Inc | 2 | $32 |
| Cordis US CORP. | 1 | $24 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 916 | $846,107 |
| Repatha SureclickEvolocumab | 236 | $145,958 |
| XareltoRivaroxaban | 158 | $133,736 |
| BrilintaTicagrelor | 191 | $84,669 |
| Praluent PenAlirocumab | 102 | $55,286 |
| Repatha SyringeEvolocumab | 35 | $19,147 |
| Metoprolol Succinate | 923 | $15,201 |
| Rosuvastatin Calcium | 993 | $13,753 |
| Ezetimibe | 433 | $11,937 |
| EntrestoSacubitril/Valsartan | 15 | $10,483 |
| Atorvastatin Calcium | 853 | $9,032 |
| Potassium Chloride | 308 | $5,995 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 373 | $4,332 |
| Amlodipine Besylate | 875 | $3,947 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 145 | $3,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $846,107916 claims |
| Johnson & JohnsonXarelto | $510 | $133,736158 claims |
| AstraZenecaBrilinta | $222 | $84,669191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Sioux Falls
- Adam StysSioux Falls$155K
- John WagenerSioux Falls$123K
- Thomas WaterburySioux Falls$13K
- Sean HalliganSioux Falls$12K
- Marian PetraskoSioux Falls$4K
- Raymond AllenSioux Falls$885
- Jeremy ScottSioux Falls$344
- Tarek MahrousSioux Falls$178
- Joseph TumaRapid City$154K
- Thomas WilsonRapid City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.